MOUTHEE MEDIA LLC Ann Arbor, MI 2012 to 2014 Restaurant Recommendation InternBR GUEST HOSPITALITY New York, NY Jun 2013 to Aug 2013 Corporate InternFORTRESS INVESTMENT GROUP, LLC New York, NY Jun 2012 to Aug 2012 Private Equity InternALPHA EPSILON PI FRATERNITY OMEGA DEUTERON CHAPTER Ann Arbor, MI 2012 to 2012 Steward
Education:
College of Literature May 2014 Bachelor of Arts in Organizational StudiesUNIVERSITY OF MICHIGAN Ann Arbor, MI Master in Management
Oct 2009 to Present Learning Center TeacherCollinsville Child Care Center
Aug 2009 to Present Head TeacherTeaneck Board of Education Teaneck, NJ Oct 2008 to Jan 2010 Substitute TeacherWest New York Board of Education West New York, NJ Jan 2008 to May 2008 Student TeacherEnglewood Board of Education Englewood, NJ Nov 2007 to Jan 2008 AVID TutorCyber Robotics Learning Center Closter, NJ Sep 2007 to Jan 2008 Robotics InstructorNJCU Early Childhood Learning Center Jersey City, NJ Jan 2007 to May 2007 Student Teacher/Practicum StudentNew Milford Board of Education New Milford, NJ Mar 1999 to Jun 2000 Teachers Aide for the Latch Key ProgramTemple Emeth Religious School Teaneck, NJ Sep 1994 to May 2000 Volunteer Religious School Aide
Education:
New Jersey City University Sep 2004 to May 2008 Bachelor in Early Childhood EducationBergen Community College Sep 2002 to May 2004 Early Childhood EducationFairleigh Dickenson University Sep 2000 to Dec 2002New Milford High School Sep 1996 to Jun 2000
Goodwin Procter 599 Lexington Avenue, New York, NY 10022
Licenses:
New York - Currently registered 2006
Education:
George Washington University National Law Center Degree - JD - Juris Doctor - Law Graduated - 1996 Hamilton College Law School Degree - JD - Juris Doctor - Law Graduated - 1993
Specialties:
Business - 50% Government - 25% Financial Markets And Services - 25%
Dr. Stern graduated from the Mount Sinai School of Medicine in 1977. He works in Rockville, MD and 1 other location and specializes in Gastroenterology. Dr. Stern is affiliated with Adventist Healthcare Shady Grove Medical Center and Medstar Montgomery Medical Center.
A liquid pharmaceutical composition is disclosed comprising calcitonin or an acid addition salt thereof and citric acid or salt thereof in a concentration from about to about 50 mM, said composition being in a form table for nasal administration.
Oral Delivery Of Peptides Using Enzyme-Cleavable Membrane Translocators
Bioavailability of peptide active agents to be administered orally is enhanced by a pharmaceutical composition providing targeted release of the peptide to the intestine in addition to having the active peptide linked to a membrane translocator which is capable of being at least partially cleaved in vivo by an enzyme. The composition includes an acid-resistant protective vehicle which transports components of the invention through the stomach and a sufficient amount of a pH-lowering agent to lower local intestinal pH. All components are released together into the intestine with the peptide.
A finished pharmaceutical product adapted for oral delivery of a physiologically active peptide agent, wherein the product comprises a therapeutically effective amount of the active peptide agent; at least one pharmaceutically acceptable pH-lowering agent; and at least one absorption enhancer effective to promote bioavailability of the active agent, wherein the pH-lowering agent is present in the finished pharmaceutical product in a quantity which, if the product were added to 10 milliliters of 0. 1M aqueous sodium bicarbonate solution, would be sufficient to lower the pH of the solution to no higher than 5. 5, and wherein an outer surface of the product is substantially free of an acid-resistant protective vehicle. The product is adapted for use in a method for enhancing the bioavailability of a therapeutic peptide active agent delivered orally.
William Stern - Tenafly NJ, US Angelo P. Consalvo - Monroe NY, US
Assignee:
Unigene Laboratories Inc. - Boonton NJ
International Classification:
A61K 38/00 A61K 47/12
US Classification:
514 11, 424465, 562400
Abstract:
Acid-containing oral pharmaceutical compositions are provided wherein the pharmaceutical active agents are peptide compounds (i. e. , those that include a plurality of amino acids and at least one peptide bond in their molecular structures). Certain barrier layers and/or particulate coated acid are used to reduce any adverse interactions that might otherwise occur between the acid of the compositions and other components of the composition. Use of these barrier layers and/or use of particulate coated acid is believed to promote a more simultaneous release of the components of the composition than is achieved by prior art acid-protection techniques, thus enhancing, and making more consistent, the bioavailability of the active peptide compounds.
William Stern - Tenafly NJ, US Angelo P. Consalvo - Monroe NY, US
Assignee:
Enteris Biopharma, Inc. - Boonton NJ
International Classification:
A61K 38/00 A61K 47/12
US Classification:
514 11, 562400, 562584, 424465
Abstract:
Acid-containing oral pharmaceutical compositions are provided wherein the pharmaceutical active agents are peptide compounds (i. e. , those that include a plurality of amino acids and at least one peptide bond in their molecular structures). Certain barrier layers and/or particulate coated acid are used to reduce any adverse interactions that might otherwise occur between the acid of the compositions and other components of the composition. Use of these barrier layers and/or use of particulate coated acid is believed to promote a more simultaneous release of the components of the composition than is achieved by prior art acid-protection techniques, thus enhancing, and making more consistent, the bioavailability of the active peptide compounds.
William Stern - Tenafly NJ, US Angelo P. Consalvo - Monroe NY, US
Assignee:
Enteris Biopharma, Inc. - Boonton NJ
International Classification:
A61K 38/00
US Classification:
514 11, 424465, 562584, 514 119
Abstract:
Acid-containing oral pharmaceutical compositions are provided wherein the pharmaceutical active agents are peptide compounds (i. e. , those that include a plurality of amino acids and at least one peptide bond in their molecular structures). Certain barrier layers and/or particulate coated acid are used to reduce any adverse interactions that might otherwise occur between the acid of the compositions and other components of the composition. Use of these barrier layers and/or use of particulate coated acid is believed to promote a more simultaneous release of the components of the composition than is achieved by prior art acid-protection techniques, thus enhancing, and making more consistent, the bioavailability of the active peptide compounds.